Biosensors

Biosensors: stock is down 1.4% at $1.37, extending losses for the 6th consecutive day. KE Research highlighted yday that there is growing concern over ASP trends for drug eluting stents (DES), which is Biosensors' key pdt. Industry sources expect Beijing's new DES tender process to lead to a 15% px cut, which could erode Biosensors' margins. China is estimated to account for 30% of Biosensors' total revenue. The house lowered TP to $1.82 from $1.67, though it kept its Buy rating.